On-Demand CME Videos
FC24: Evolving Therapies in the Treatment of Chronic Spontaneous Urticaria: An Online Activity
About
Evolving Therapies in the Treatment of Chronic Spontaneous Urticaria: An Online Activity
This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals, Inc.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 12, 2024
December 12, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe strategies to diagnose patients with chronic spontaneous urticaria (CSU)
Describe the role of evolving therapies in the treatment and management of CSU
Identify strategies to incorporate evolving therapies for the management of CSU into dermatological clinical practice
Intended Audience
Faculty
Brad Glick, DO, MPH
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Hialeah, FL
David Lang, MD
Chairman of the Department of Allergy and Clinical Immunology at the Cleveland Clinic
Cleveland, Ohio
Dawn Merritt, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Ownership interest: Top MD stock
No relevant financial relationships with any Ineligible Company in the past 24 months.
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.